Article Sidebar
Views PDF: 56
INITIAL ASSESSMENT THE VALUE OF INTERIM PET/CT AFTER 2 CYCLES OF ABVD CHEMOTHERAPY IN HODGKIN LYMPHOMA PATIENTS
Main Article Content
Abstract
Purpose: The study aimed to initial evaluate the value of interim PET/CT after 2 cycles of ABVD chemotherapy in Hodgkin lymphoma patients.Material and Methods: The study was carried out retrospective and prospective descriptive study on 56 patients at Tan Trieu K Hospital from March 2020 to June 2022. Patients were examined clinically, paraclinically, had a CT scan or PET/CT film before treatment, then received ABVD chemotherapy, after 2 cycles of being taken and evaluated Interim PET/CT, and continued treatment based on the results. Result of iPET/CT leads to continue or change of regimen continued treatment or change of regimen and follow-up.
Results: In a total of 56 patients, male/female ratio: 1/1.6, mean age 30±12.6 (youngest age 7 years old, oldest age 67 years old). 35/56 patients (62.5%) had CT scan and 21/56 patients (37.5%) had background PET/CT scan before treatment. 30.4% had 2 lymph node sites and 28.6 patients had 3 lymph node sites on the body, lymph nodes above the diaphragm 67.9% and lymph nodes both above and below the diaphragm 12,5%. 49 patients had lymph node lesions, short axis size of lymph nodes maximum 27.10±8.3 mm. Lesion to the mediastinum in 15/58 patients (25.8%), spleen in 5 patients. Patients with early stage I-II accounted for 82.1%, advanced stage III-IV accounted for 17.9%. After 2 cycles of ABVD chemotherapy, the response rate on PET/CT was iPET/CT2 (-) 43/56 patients (76.8%, of which Deuville score 1 point 93%) and iPET/CT2 (+) in 13/56 patients (23.3%). The prognostic index of IPS low-risk group (0-2) complete metabolic response was 86.4%. In the high-risk group IPS (4-7) partial metabolic response and complete metabolic response was 54.5% according to Lugano classification.
Conclusion: Interim PET/CT has an important role in providing prognostic information in the treatment of ABVD chemotherapy in Hodgkin Lymphoma patients, reducing the toxicity of chemotherapy and determining the next treatment modalities.
Article Details
Keywords
lymphoma Hodgkin, interim PET/CT.
References
2. Ung thư, Bộ Môn Ung Thư (2015), Bệnh Hodgkin, Ung thư học, Trường Đại Học Y Hà Nội, Nhà xuất bản y học, pp, 294-302
3. Cheson, B. D. (2015). Staging and response assessment in lymphomas: the new Lugano classification. Chinese clinical oncology, 4(1), 5-5.
4. Cerci J.J., Pracchia L.F., Linardi C.C.G., et al. (2010). 18 F-FDG PET After 2 Cycles of ABVD Predicts Event-Free Survival in Early and Advanced Hodgkin Lymphoma. J Nucl Med, 51(9), 1337–1343
5. Gallamini A., Hutchings M., Rigacci L., et al. (2007). Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol, 25(24), 3746–3752.
6. Gallamini A., Barrington S.F., Biggi A., et al. (2014). The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica, 99(6), 1107–1113.
7. (2020). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Hodgkin Lymphoma, 5.
8. Seshachalam, A., Karpurmath, S. V., Rathnam, K., Raman, S. G., Janarthinakani, M., Prasad, K., ... & Shewade, H. D. (2019). Does interim PET scan after 2 cycles of ABVD predict outcome in Hodgkin lymphoma? Real-world evidence. Journal of global oncology, 5, 1-13.